Phase I Single-dose Escalation Clinical Trial of Salvianolic Acid A Tablets
Status:
Unknown status
Trial end date:
2019-05-20
Target enrollment:
Participant gender:
Summary
Salvianolic acid A has a variety of pharmacological effects, such as: anti-oxidation,
scavenging oxygen free radicals, anti-fibrosis, anti-myocardial ischemia, anti-coagulation,
anti-thrombosis, anti-tumor, etc. Professor Du Guanhua, at Institue of Materia Medica,
Chinese Academy of Medical Sciences, first discovered that salvianolic acid A can alleviate
diabetic complications and improve patients' quality of life. With the support of major
national science and technology projects, the preclinical research work of salvianolic acid A
was completed, and the application was approved by the State Food and Drug Administration
(Clinical Approval No.: 2016L06293). Peking University First Hospital was used as the
research unit. This study is the first human clinical trial of the drug. The project leader
of this study is Professor Cui Yimin from Peking University First Hospital. The sponsor of
this project is Shandong Huizhi Pharmaceutical Technology Co., Ltd.
Phase:
Phase 1
Details
Lead Sponsor:
Peking University First Hospital
Collaborators:
Chinese Academy of Medical Sciences Institute of Materia Medica, Chinese Academy of Medical Sciences Shandong Huizhi Pharmaceutical Technology Co., Ltd.